A systematic review of metabolomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis/Systemic Exertion Intolerance Disease (CFS/ME/SEID).
Huth, Teilah Kathryn, Eaton-Fitch, Natalie, Staines, Donald et al. · Journal of translational medicine · 2020 · DOI
Quick Summary
Researchers reviewed 11 studies that measured tiny chemical molecules (metabolites) in the blood and urine of ME/CFS patients to see if problems with these chemicals might explain the illness. While they found some patterns—especially with chemicals related to amino acids (building blocks of proteins)—the results were inconsistent across different studies. The researchers concluded that we don't yet have enough evidence that metabolite problems cause ME/CFS.
Why It Matters
Understanding whether metabolic dysfunction drives ME/CFS symptoms is crucial for developing targeted treatments and biomarkers for diagnosis. This review identifies critical gaps in how metabolomics research is currently conducted, providing researchers with a roadmap for designing more rigorous studies that could eventually establish metabolic abnormalities as disease mechanisms or diagnostic markers.
Observed Findings
Amino acid pathway metabolites were most frequently reported as abnormal, appearing in 7 out of 10 blood studies
No single specific metabolite was consistently impaired across all studies examined
Only 3 of 11 studies measured urine metabolites, with inconsistent results
Significant heterogeneity existed in diagnostic criteria, metabolite analysis methods, and study designs across included studies
All 11 studies met quality assessment criteria, but research design inconsistency remained a major limitation
Inferred Conclusions
Current metabolomics research in ME/CFS lacks sufficient consistency and standardization to definitively establish metabolic dysfunction as a pathogenic factor
Amino acid metabolism may be involved in ME/CFS pathophysiology, but this requires confirmation through standardized research approaches
Future metabolomics research must employ uniform diagnostic criteria, analytical methods, and control for confounding factors to generate meaningful evidence
Remaining Questions
Why do amino acid metabolite abnormalities appear in multiple studies but show inconsistent patterns across them?
What specific metabolic pathways are most relevant to ME/CFS symptomatology, and how should they be prioritized in future research?
What This Study Does Not Prove
This review does not prove that metabolic problems cause ME/CFS or are the primary mechanism of illness—it only shows that current evidence is too inconsistent to draw such conclusions. The findings do not rule out metabolic involvement; rather, they indicate that better-designed studies with standardized methods are needed to determine whether metabolic dysfunction is truly linked to disease pathogenesis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How do confounding factors (exercise, diet, medications, comorbidities) influence metabolite levels in ME/CFS patients, and how can studies best control for these?
Would longitudinal metabolomic studies tracking individual patients over time reveal more consistent patterns than cross-sectional case-control designs?